Artikel
Functional characterization of an endo-fucoidanase from Formosa haliotis for the degradation of α-(1–3) and α-(1–4) fucoidans
Suche in Medline nach
Autoren
Veröffentlicht: | 7. Oktober 2020 |
---|
Gliederung
Text
Fucoidans are complex and heterogeneous sulfated polysaccharides found in the cell wall of brown algae. They present a large variety of structures and have gained an increased interest over the last decades as they can be potentially used for a wide range of applications. Particularly, fucoidan oligosaccharides display an extensive panel of valuable biological activities, such as antioxidant, anticancer, anti-inflammatory, anticoagulant and possess immune-modulatory properties [1].
However, the heterogeneous structure, the viscosity and the large size of the natural fucoidan polysaccharides render them unsuitable for clinical use. Moreover, it is frequently observed that the bioactivity of fucoidans are improved when the molecular weight is lower [2].
Endo-fucoidanases (EC 3.2.1.-) are enzymes that catalyze the hydrolysis of glycosidic bonds between sulfated fucosyl residues in fucoidan polysaccharides [3]. They belong to the CAZy family GH107 of the Glycoside Hydrolases [4]. This quite recent family contains only a very few members up to date: 17 fucoidanases of bacterial origin have been reported in the CAZy database and only six of them have been functionally characterized.
In this study, we aimed to expand the repertoire of known GH107 and identify new tools for the enzymatic synthesis of fucooligosaccharides. We recently identified three genes coding for putative fucoidanases in the genome of the brown-algae-degrading bacterium Formosa haliotis. In this talk, we will present our recent findings on the identification and the characterization of one of the putative fucoidanase named Fhf1. We hope this work will contribute to the better understanding of the structure-function relationships of the GH107 family and will provide new tools for the synthesis of novel active biomolecules.
References
- 1.
- Fitton HJ, Stringer DS, Park AY, Karpiniec SN. Therapies from Fucoidan: New Developments. Mar Drugs. 2019;17(10):571. Published 2019 Oct 9. DOI: 10.3390/md17100571
- 2.
- Song MY, Ku SK, Kim HJ, Han JS. Low molecular weight fucoidan ameliorating the chronic cisplatin-induced delayed gastrointestinal motility in rats. Food Chem Toxicol. 2012;50(12):4468-4478. DOI: 10.1016/j.fct.2012.09.020
- 3.
- Lombard V, Golaconda Ramulu H, Drula E, Coutinho PM, Henrissat B. The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res. 2014;42(Database issue):D490-D495. DOI: 10.1093/nar/gkt1178
- 4.
- Colin S, Deniaud E, Jam M, et al. Cloning and biochemical characterization of the fucanase FcnA: definition of a novel glycoside hydrolase family specific for sulfated fucans. Glycobiology. 2006;16(11):1021-1032. DOI: 10.1093/glycob/cwl029